Leanne Peiser
Board Observer @Be Biopharma
Signup · Get unlimited contacts
WORK HISTORY
Board Observer @Be Biopharma
EDUCATION
University of Cape Town
B.Sc (MED)(HONS), Medical Biochemistry
University of Cape Town
B.Sc., Microbiology, Biochemistry
University of Oxford
D.Phil, Immunology
SKILLS
ABOUT LEANNE PEISER
Executive Leadership & Strategic Impact : Seasoned executive with 20+ years leading translational and discovery teams across Amgen, Gilead, FLXBio, and BMS. Currently oversee ~35 scientists at BMS, delivered 30+ IND-enabling packages and clinical insights for cell therapy and immuno-oncology programs. Influenced portfolio decisions through department-wide strategy, BD and governance presentations.Discovery & Translational Excellence: Helped advance >15 novel therapeutics to IND across autoimmune, oncology, and infectious diseases. Delivered and led translational strategy for 40+ clinical-stage programs, supporting 30+ INDs and 9 global submissions across modalities including CAR T, small molecules, ADCs, bispecifics, and immune engagers (TCE, NKE).Regulatory & Global Leadership: Global translational lead for Breyanzi, contributing to BLA filings across 4 approved indications and 9 global submissions. Authored pivotal sections of INDs, sBLAs, and led health authority interactions across US, EU, and APAC.Organizational Development & Talent Growth: Managed and mentored >50 scientists over two decades. Promoted >20 team members, including high-visibility rapid advancement cases recognized in HR and leadership forums. Built resilient, high-performing teams with >90% retention.Cross-Functional & Enterprise Alignment : Served as translational SME across early discovery, BD diligence, and clinical development. Partnered with to shape business investments and partnerships, therapeutic area and clinical development strategies.Scientific & Innovation Leadership: Recognized expert in CAR T biology, macrophages, and MDSCs. Led rationale development for next-gen CART and immunotherapy programs. Piloted GenAI tools for translational data analysis, improving operational efficiency.Global Reach & Strategic Collaborations: Expanded BMS’s cell therapy footprint across hematology, immunology, and oncology. Supported international CTA filingsand strategic collaborations with Stanford University, MDACC, Imperial College among others enhancing scientific visibility and regulatory reach
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.